According to Zacks, “HeidelbergCement AG operates as a building materials manufacturer. It engages in the production and distribution of cement and aggregates. The Company also offers ready-mixed concrete, concrete products, and concrete elements, as well as other related products and services. It has operations in sub-Saharan Africa: Benin, DR Congo, Gabon, Ghana, Liberia, Sierra Leone, Tanzania, and Togo. HeidelbergCement AG is headquartered in Heidelberg, Germany. “
Several other research firms have also recently commented on HDELY. Societe Generale restated a sell rating on shares of HEIDELBERGCEMEN/ADR in a report on Monday, May 20th. Berenberg Bank restated a sell rating and issued a GBX 65 ($0.85) price target on shares of AA in a report on Thursday, April 4th. Kepler Capital Markets restated a hold rating on shares of HEIDELBERGCEMEN/ADR in a report on Tuesday, July 9th. ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. Finally, Barclays restated an underweight rating and issued a GBX 600 ($7.84) price target on shares of in a report on Monday, July 8th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $17.00.
HeidelbergCement AG produces and distributes cement, aggregates, ready-mixed concrete, and asphalt worldwide. The company offers cement products, including special cements with targeted characteristics, special geotechnical building materials, and a range of binders. It also provides natural stone aggregates, comprising sand and gravel; crushed aggregates, such as stone chippings and crushed stones; and concrete/ready-mixed concrete for the production of precast concrete parts consisting of stairs, ceiling elements, or structural components, as well as for use in the construction of tunnels or bridges, office buildings, or schools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HEIDELBERGCEMEN/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HEIDELBERGCEMEN/ADR and related companies with MarketBeat.com's FREE daily email newsletter.